{"entity":{"id":"crispr-therapeutics","kind":"company","name":"CRISPR Therapeutics","aka":["CRISPR Therapeutics AG","NASDAQ:CRSP"],"tldr":"CRISPR Therapeutics is the gene-editing company co-founded by Emmanuelle Charpentier that shares Casgevy with Vertex and is building off-the-shelf CAR-T cells such as CTX112 for lymphoma and autoimmune disease.","summary":"CRISPR Therapeutics, headquartered in Zug with research in Boston, uses CRISPR/Cas9 to make gene-edited medicines. With Vertex it brought exagamglogene autotemcel (Casgevy) to approval for sickle cell disease and beta thalassaemia. In oncology it develops allogeneic CAR-T cells made from healthy donor T cells: CTX112 targets CD19 in B-cell malignancies and lupus, and CTX131 targets CD70 in solid tumours and haematological cancers. The company also has in vivo editing programmes for cardiovascular disease.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.crisprtx.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["ctx112"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Zug","country":"CH","companyType":"cell-therapy","website":"https://www.crisprtx.com/","ticker":"NASDAQ:CRSP","founded":2013,"stage":"public","investors":[],"funding":[]},"route":"/companies/crispr-therapeutics/","neighbours":{"drug":[{"id":"ctx112","kind":"drug","name":"CTX112","route":"/drugs/ctx112/"}]}}